[Clinical practice guidelines for spinal muscular atrophy]

Area of Science:

• Genetics
• Pediatrics
• Neurology

Background:

• Spinal muscular atrophy (SMA) is a frequent, fatal, autosomal recessive genetic disorder in infants.
• It results from mutations in the motor neuron survival gene 1 (SMN1), with incidence rates varying by ethnicity.
• SMA is classified into types I-IV based on onset and clinical presentation, with 95% of patients having homozygous deletions in SMN1 exon 7.

Purpose of the Study:

• To provide a comprehensive guideline for the diagnosis and treatment of SMA.
• To standardize clinical management and genetic counseling for SMA patients.
• To reduce the incidence of births affected by SMA through improved awareness and intervention.

Main Methods:

• Review of relevant domestic and international research, guidelines, and consensus statements.
• Analysis of clinical manifestations and pathogenesis of SMA.
• Compilation of experiences in SMA diagnosis and genetic counseling.

Main Results:

• Identified challenges in early diagnosis, genetic consultation, treatment, and prevention due to SMA's complex genetic factors and high carrier rates.
• Summarized current knowledge on SMA pathogenesis and clinical phenotypes.
• Highlighted the importance of genetic counseling and standardized diagnostic approaches.

Conclusions:

• Standardized diagnosis and treatment are essential for effective SMA management.
• Genetic counseling plays a vital role in preventing affected births.
• Further research and updated guidelines are needed to address the complexities of SMA.